1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/57769
Full metadata record
DC FieldValueLanguage
dc.creatorAriane Vieira Scarlatelli Macedopt_BR
dc.creatorAngelica Nogueira Rodriguespt_BR
dc.creatorRafael Brant Costapt_BR
dc.creatorAntonio Luiz Pinho Ribeiropt_BR
dc.date.accessioned2023-08-11T20:44:39Z-
dc.date.available2023-08-11T20:44:39Z-
dc.date.issued2019-09-
dc.citation.volume1pt_BR
dc.citation.issue1pt_BR
dc.citation.spage68pt_BR
dc.citation.epage79pt_BR
dc.identifier.issn0732-183Xpt_BR
dc.identifier.urihttp://hdl.handle.net/1843/57769-
dc.description.resumoOBJECTIVES: The authors performed a systematic review and meta-analysis of randomized and nonrandomized trials on the efficacy of dexrazoxane in patients with breast cancer who were treated with anthracyclines with or without trastuzumab.BACKGROUND: Breast cancer treatment with anthracyclines and trastuzumab is associated with an increased risk of cardiotoxicity. Among the various strategies to reduce the risk of cardiotoxicity, dexrazoxane is an option for primary prevention, but it is seldom used in clinical practice. METHODS: Online databases were searched from January 1990 up to March 1, 2019, for clinical trials on the use of dexrazoxane for the prevention of cardiotoxicity in patients with breast cancer receiving anthracyclines with or without trastuzumab. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model meta-analysis.RESULTS: Seven randomized trials and 2 retrospective trials with a total of 2,177 patients were included. Dexrazoxane reduced the risk of clinical heart failure (RR: 0.19; 95% CI: 0.09 to 0.40; p < 0.001) and cardiac events (RR: 0.36; 95% CI: 0.27 to 0.49; p < 0.001) irrespective of previous exposure to anthracyclines. The rate of a partial or complete oncological response, overall survival, and progression-free survival were not affected by dexrazoxane.CONCLUSIONS: Dexrazoxane reduced the risk of clinical heart failure and cardiac events in patients with breast cancer undergoing anthracycline chemotherapy with or without trastuzumab and did not significantly impact cancer outcomes.However, the quality of available evidence is low, and further randomized trials are warranted before the systematic implementation of this therapy in clinical practice.pt_BR
dc.format.mimetypepdfpt_BR
dc.languageengpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentMEDICINA - FACULDADE DE MEDICINApt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofJournal of Clinical Oncology-
dc.rightsAcesso Restritopt_BR
dc.subjectBreast cancerpt_BR
dc.subjectAnthracyclinespt_BR
dc.subjectTrastuzumabpt_BR
dc.subject.otherCancer de colo de úteropt_BR
dc.subject.otherAntraciclinaspt_BR
dc.subject.otherTrastuzumabpt_BR
dc.titleCardioprotective effect and safety of dexrazoxane in all breast cancer stages in patients treated with anthracyclines with or without trastuzumab: a systematic review and meta-analysis.pt_BR
dc.typeArtigo de Periódicopt_BR
dc.url.externahttps://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.10072pt_BR
Appears in Collections:Artigo de Periódico

Files in This Item:
There are no files associated with this item.
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.